Allianz X backs Amwell’s Series C round

Boston-based telehealth company Amwell  announced it has closed a $194 million Series C round, bringing its total funding to over $710 million. Many early investors and strategic partners participated in this round, including Allianz X and Takeda. Amwell will use significant parts of the funds to expand its investment in technology and services that make it easy, convenient and effective for doctors and patients to connect securely at scale. Amwell will continue to ensure that clinical encounters remain fully integrated in existing workflows and enveloped with healthcare-appropriate clinical and administrative information, management, and reporting.

“The past two months have accelerated telehealth by more than two years. We intend to build upon this momentum to transform healthcare with digital care delivery. Our strategic investors are providers, insurers, consumer gateways and healthcare innovators. Each of these partners play a key role in creating a more interconnected digital healthcare ecosystem, where our mission is to deliver greater access to more affordable, high quality care.” – Ido Schoenberg, CEO of Amwell.

“Being an investor and partner to Amwell since early 2018, Allianz is excited to see the company emerge as a digital healthcare leader in the U.S. As one of the leading insurance and financial services leaders in the world, we look forward to deepening our collaboration and bringing innovative solutions to a global audience.” – Nazim Cetin, CEO of Allianz X.